Tafamidis ATTR Cm denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tafamidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Tafamidis-Attr-Cm — and How to Navigate the Process

UHC's prior authorization requirement for tafamidis in ATTR cardiomyopathy (ATTR-CM) exists because the drug is high-cost and indicated for a specific, diagnosis-confirmed population. This is a standard utilization management tool — it does not mean UHC considers the drug experimental or inappropriate. What it means is that the clinical documentation must be assembled correctly before coverage is granted.

PA denials at UHC for tafamidis most commonly arise because: the ATTR-CM diagnosis was not documented with sufficient specificity in the PA request, the required diagnostic workup records were not submitted, the prescriber's letter did not address each of UHC's published clinical criteria, or the referral came from a provider outside UHC's preferred specialty designation for this drug.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): A PA denial is an adverse benefit determination that triggers full internal appeal rights. Request UHC's denial letter identifying each criterion that was not met, and its current clinical coverage policy for tafamidis.
• Peer-to-peer review: Ask UHC whether your cardiologist can speak directly with UHC's medical reviewer before or during the internal appeal. Peer-to-peer conversations frequently resolve PA denials faster than written appeals when the prescriber can address specific documentation gaps in real time.
• External review: If the internal appeal is denied, request IRO review. The IRO is not bound by UHC's clinical criteria — it applies independent medical standards. Federal law provides approximately four months from the adverse determination to initiate external review. Expedited review is available when delay poses clinical risk.

## Documentation to Gather

1. ATTR-CM diagnostic records — the full diagnostic workup confirming ATTR-CM: nuclear scintigraphy report, echocardiogram or cardiac MRI, and genetic testing results if hereditary subtype. Include the interpreting cardiologist's interpretation. 2. Disease subtype documentation — confirm in writing whether the diagnosis is wild-type (wtATTR-CM) or hereditary/variant (vATTR-CM), as UHC's criteria may treat these differently. 3. Clinical severity assessment — functional status documentation from the chart, including NYHA class as documented by the treating cardiologist. 4. Prior cardiac treatment history — all prior therapies, with dates and clinical response. 5. Prescriber medical-necessity letter — your cardiologist should obtain UHC's current published PA criteria for tafamidis/ATTR-CM and address each criterion explicitly, citing specific chart entries by date. 6. FDA-approved prescribing label — attach as a supporting exhibit to confirm the approved indication matches the patient's diagnosis.

## Criteria-Mapping Structure

| UHC PA Criterion | Patient-Specific Documentation | |---|---| | Confirmed ATTR-CM diagnosis | [Diagnostic method, date, interpreting physician] | | Disease subtype | [Wild-type or hereditary, confirmed by] | | Cardiac assessment | [Echo/MRI/scan date and findings per cardiologist] | | NYHA functional class | [As documented in chart on date X] | | Prescriber is cardiologist | [Name, NPI, specialty] | | FDA indication match | [Attached FDA label, highlighted] |

Obtain UHC's current clinical coverage policy before drafting the prescriber letter — criteria change, and a letter written to outdated criteria may miss a new requirement.